About

Dr. Ivana Magovčević-Liebisch has served on Acrivon's Board since February 2024. She is President and CEO of Draig Therapeutics, a role she assumed after serving as President and CEO of Vigil Neuroscience until its acquisition by Sanofi in August 2025. She was previously Executive Vice President and Chief Business Officer at Ipsen from 2018 to 2020. She currently serves on the boards of Quanterix Corporation and Draig Therapeutics and was previously chairperson of the board of Absci and a director of Aeglea BioTherapeutics and Applied Genetic Technologies. She holds a Ph.D. in genetics from Harvard University, a J.D. from Suffolk University Law School and a B.A. in biology and chemistry from Wheaton College. She serves on Acrivon's Audit Committee.

Roles

Acrivon Therapeutics, Inc.
Director · Current role
February 2024–present
Draig Therapeutics, Ltd.
President & Chief Executive Officer
2025 - present
Vigil Neuroscience, Inc.
President & Chief Executive Officer
2021 - 2025
Ipsen
EVP & Chief Business Officer
2018 - 2020

External Roles

Quanterix Corporation
Director
—
Draig Therapeutics, Ltd.
Director
—
Absci Corporation
Chairperson of the Board
—
Aeglea BioTherapeutics, Inc.
Director
—

Director Compensation

FY 2025
Fees earned or paid in cash
$47,500
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$17,870
ComponentStock options granted during 2025, ASC 718 grant-date fair value
Total
$65,370

Also at Acrivon Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.